Nasdaq · CIK 0001841330
KTTA Pasithea Therapeutics Corp.
Insider trading from SEC Form 4. Last filing Jun 22, 2026. Close $0.47 on Oct 9, 2026, +60% from the 52-week low and -68% from the high.
In brief
Pasithea Therapeutics Corp. (KTTA) has 20 SEC Form 4 filings on file from 8 insiders, the latest filed on Jun 22, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
5 open-market trades have been scored at KTTA. The newest: Coastlands Capital LP (10% owner) bought $53k of stock on Jun 17, 2026, filed Jun 22, 2026, scored 22 (weak). The largest of the 5 shown: Lawrence Steinman (director) bought $100k on Nov 28, 2025, scored 50 (moderate). 3 insiders bought within 14 days of each other around Nov 28, 2025.
1 Form 144 notice of planned sales is on file, the latest filed May 14, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Pasithea Therapeutics Corp., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | Coastlands Capital LP owner buy | $53k 100,000 shares | +3% | +72% from low-66% from high | |
| 40Moderate | Simon Dumesnil director buy | $25k 33,333 shares | +1333% | - | |
| 50Moderate | Tiago Marques Chief Executive Officer buy | $25k 33,333 shares | +83% | - | |
| 50Moderate | Lawrence Steinman director buy | $100k 133,333 shares | +201% | - | |
| 25Weak | Tiago Marques Chief Executive Officer sell | $792 960 shares | -2% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 14, 2025 | Tiago Reis Marques Officer, Director | 960 0.01% of outstanding | $798 | May 12, 2025 | none |
Transactions
Every row filed, 20 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Coastlands Capital LP owner | POpen-market purchase Common Stockindirect: By Coastlands Capital LP | +100,000 | $0.53 | $53k | 3,835,035 | Jun 22, 2026 |
| May 1, 2026 | Simon Dumesnil director | AGrant or award Stock Option (right to buy)derivative | +152,783 | $0.00 | $0 | 152,783 | May 5, 2026 |
| May 1, 2026 | Kartik Krishnan Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +1,129,323 | $0.00 | $0 | 1,129,323 | May 5, 2026 |
| May 1, 2026 | Emer Leahy director | AGrant or award Stock Option (right to buy)derivative | +152,783 | $0.00 | $0 | 152,783 | May 5, 2026 |
| May 1, 2026 | Tiago Marques Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +1,756,069 | $0.00 | $0 | 1,756,069 | May 5, 2026 |
| May 1, 2026 | Alfred J Novak director | AGrant or award Stock Option (right to buy)derivative | +152,783 | $0.00 | $0 | 152,783 | May 5, 2026 |
| May 1, 2026 | Daniel H Schneiderman Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +1,129,323 | $0.00 | $0 | 1,129,323 | May 5, 2026 |
| May 1, 2026 | Lawrence Steinman director | AGrant or award Stock Option (right to buy)derivative | +152,783 | $0.00 | $0 | 152,783 | May 5, 2026 |
| Nov 28, 2025 | Tiago Marques Chief Executive Officer | POpen-market purchase Common Stock | +33,333 | $0.75 | $25k | 73,334 | Dec 1, 2025 |
| Nov 28, 2025 | Lawrence Steinman director | POpen-market purchase Common Stock | +133,333 | $0.75 | $100k | 199,691 | Dec 1, 2025 |
| Nov 28, 2025 | Daniel H Schneiderman Chief Financial Officer | AGrant or award Common Stock | +26,667 | $0.75 | $20k | 26,667 | Dec 1, 2025 |
| Nov 28, 2025 | Emer Leahy director | AGrant or award Common Stock | +33,333 | $0.75 | $25k | 33,333 | Dec 1, 2025 |
| Nov 28, 2025 | Simon Dumesnil director | POpen-market purchase Common Stock | +33,333 | $0.75 | $25k | 35,833 | Dec 1, 2025 |
| Oct 24, 2025 | Simon Dumesnil director | AGrant or award Stock Option (right to buy)derivative | +42,913 | $0.00 | $0 | 42,913 | Oct 27, 2025 |
| Oct 24, 2025 | Emer Leahy director | AGrant or award Stock Option (right to buy)derivative | +42,913 | $0.00 | $0 | 42,913 | Oct 27, 2025 |
| Oct 24, 2025 | Tiago Marques Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +493,341 | $0.00 | $0 | 493,341 | Oct 27, 2025 |
| Oct 24, 2025 | Alfred J Novak director | AGrant or award Stock Option (right to buy)derivative | +42,913 | $0.00 | $0 | 42,913 | Oct 27, 2025 |
| Oct 24, 2025 | Daniel H Schneiderman Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +317,266 | $0.00 | $0 | 317,266 | Oct 27, 2025 |
| Oct 24, 2025 | Lawrence Steinman director | AGrant or award Stock Option (right to buy)derivative | +242,913 | $0.00 | $0 | 242,913 | Oct 27, 2025 |
| May 12, 2025 | Tiago Marques Chief Executive Officer | SOpen-market sale Common Stock | -960 | $0.83 | $792 | 40,001 | May 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Coastlands Capital LPowner
- Simon Dumesnildirector
- Kartik KrishnanChief Medical Officer
- Emer Leahydirector
- Tiago MarquesChief Executive Officer
- Alfred J Novakdirector
- Lawrence Steinmandirector
- Daniel H SchneidermanChief Financial Officer
Questions about KTTA
Answered from the filings on this page, as of the latest one.
Are insiders buying KTTA?
No. In the last 90 days no insider at Pasithea Therapeutics Corp. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade KTTA on the open market?
Coastlands Capital LP (10% owner) bought $53k of KTTA on Jun 17, 2026 and filed the Form 4 on Jun 22, 2026. InsiderTell scored 22 (weak).
How many insiders file Form 4 at Pasithea Therapeutics Corp.?
8 people have filed a Form 4 at Pasithea Therapeutics Corp., among them Coastlands Capital LP (10% owner), Simon Dumesnil (director), Kartik Krishnan (Chief Medical Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.